Skip to main content

TYVASO is approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content
Hamburger button
Close button

PAGE NOT FOUND

We’re sorry. The page you requested could not be found.